𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study

✍ Scribed by Vladimir Novotny; Frantisek Faltus

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
84 KB
Volume
17
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

In a 6-week, multicentre, randomised, double-blind controlled study, tianeptine (37.5 mg/day) and fluoxetine (20 mg/day) were compared for efficacy and safety in 178 patients with major depression. No significant difference was shown between the two drugs, either in terms of efficacy (MADRS, CGI, COVI) or in terms of safety, except for the CGI 'severity of illness' which was lower at the end point with tianeptine than with fluoxetine. The percentages of responders (as defined by a 50% decrease of the MADRS score from baseline to end point) were 75% with tianeptine and 67% with fluoxetine, showing the efficacy of both drugs. In conclusion, both tianeptine and fluoxetine are effective and well-tolerated treatments for major depression.

πŸ“œ SIMILAR VOLUMES

Fluvoxamine versus fluoxetine in major d
Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison
✍ Jean Dalery; Adriaan Honig πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 77 KB

## Abstract A double‐blind, multinational study was conducted to compare the efficacy and safety of fluvoxamine and fluoxetine in outpatients with major depressive episode; 184 patients were randomised to fluvoxamine (100 mg/day) or fluoxetine (20 mg/day) for 6 weeks. Both drugs were effective and

A randomised, double-blind, placebo-cont
A randomised, double-blind, placebo-controlled, 5-weeks' study of org 3770 (mirtazapine) in major depression
✍ M. C. Khan πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 433 KB

Fifty-four hospitalised and outpatients with a DSM 111 diagnosis of major depressive disorder and 21-item HPRSD score of 2 18, were randomised to 5 weeks' of treatment with either Org 3770 (n=27; 20-60mg/day) or placebo (n = 27). The treatment with Org 3770 resulted in statistically significant and

Tianeptine and paroxetine in major depre
Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study
✍ Jean Pierre Lepine; Carlo Altamura; Marc Ansseau; Jose Luis Ayuso Gutierrez; Ist πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 170 KB

Tianeptine (37.5 mg/day) and paroxetine (20 mg/day) were compared in a population of depressive patients without past or current history of co-morbid anxiety and/or important anxiolytic treatment. In a 6-week, double blind trial, the special focus was on anxious symptoms.Both drugs showed good effic

Efficacy and tolerability of venlafaxine
Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram
✍ Per Allard; Lars Gram; Kristina Timdahl; Kirsten Behnke; Martin Hanson; Jesper S πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## Abstract ## Background The objectives of the study were to compare efficacy and tolerability of venlafaxine ER 75–150 mg/day with that of citalopram 10–20 mg/day in elderly patients with major depression according to DSM‐IV criteria. ## Methods A randomised, double‐blind, parallel group 6‐mon

A Double-Blind Comparison of Sertraline
A Double-Blind Comparison of Sertraline and Imipramine in Outpatients with Major Depression: Acute (8 Weeks) and Continuation (16 Weeks) Treatment
✍ J.-P. FOURNIER; R. M. LANE; G. CHOUINARD; D. B. WATSON; M. AMIN; R. A. REMICK; L πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 218 KB πŸ‘ 2 views

In a double-blind multicentre trial in patients with major depression, the ecacy and the tolerability of sertraline were compared to those of imipramine, during an 8-week acute treatment phase followed by a 16-week continuation treatment phase in treatment responders. A total of 104 patients who met